Consistent with GAS5 being a repressor of SR signaling, GAS5 is frequently downregulated in both breast and prostate cancer, suggesting a tumor‐suppressive role (Mourtada‐Maarabouni et al., 2009; Pickard et al., 2013; Figure 6b). Here, GAS5 is linked to prostate carcinoma.